ABSTRACT
Background The lung microbiome is an inflammatory stimulus whose role in chronic obstructive pulmonary disease (COPD) pathogenesis is incompletely understood. We hypothesized that the frequent exacerbator phenotype is associated with decreased α-diversity and increased lung inflammation. Our objective was to assess correlations between the frequent exacerbator phenotype, the microbiome, and inflammation longitudinally during exacerbation-free periods.
Methods We conducted a case-control longitudinal observational study of the frequent exacerbator phenotype and characteristics of the airway microbiome. Eighty-one subjects (41 frequent and 40 infrequent exacerbators) provided nasal, oral, and sputum microbiome samples at two visits over 2-4 months. Exacerbation phenotype, relevant clinical factors, and sputum cytokine values were associated with microbiome findings.
Results The frequent exacerbator phenotype was associated with lower sputum microbiome α-diversity (p=0.0031). This decrease in α-diversity among frequent exacerbators was enhanced when the sputum bacterial culture was positive (p<0.001). Older age was associated with decreased sputum microbiome α-diversity (p=0.0030). Between-visit β-diversity was increased among frequent exacerbators and those who experienced a COPD exacerbation between visits (p=0.025, p=0.014). Sputum cytokine values did not differ based on exacerbation phenotype or other clinical characteristics. IL-17A was negatively associated with α-diversity, while IL-6 and IL-8 were positively associated with α-diversity (p=0.012, p=0.012, p=0.0496). IL-22, IL-17A, and IL-5 levels were positively associated with Moraxella abundance (p=0.027, p=0.0014, p=0.0020).
Conclusions Even during exacerbation-free intervals, the COPD frequent exacerbator phenotype is associated with decreased sputum microbiome α-diversity and increased β-diversity. Decreased sputum microbiome α-diversity and Moraxella abundance are associated with lung inflammation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by U.S. Department of Veterans Affairs Office of Research and Development 1 IK2 CX001095, 1 I01 CX002130, and NIH/University of Minnesota Clinical and Translational Science Institute 1UL1RR033183, 8 UL1 TR000114-02.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the Minneapolis VA Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at NCBI.
